GCP
SRPT icon

GSA Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

GSA Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
103,618
+12,658
+14% +$239K 0.12% 194
2026
Q1 		$1.98M Buy
90,960
+20,589
+29% +$398K 0.12% 172
2025
Q4 		$1.51M Buy
70,371
+49,806
+242% +$1.05M 0.13% 172
2025
Q3 		$396K Sell
20,565
-42,060
-67% -$750K 0.03% 1012
2025
Q2 		$1.07M Buy
62,625
+39,783
+174% +$1.7M 0.08% 415
2025
Q1 		$1.46M Buy
+22,842
New +$2.4M 0.13% 179
2024
Q3 		– Sell
-2,896
Closed -$458K – 1988
2024
Q2 		$458K Sell
2,896
-2,156
-43% -$277K 0.03% 1021
2024
Q1 		$654K Sell
5,052
-1,589
-24% -$195K 0.05% 723
2023
Q4 		$640K Sell
6,641
-174
-3% -$16.7K 0.05% 631
2023
Q3 		$826K Buy
+6,815
New +$770K 0.07% 508
2023
Q1 		– Sell
-6,134
Closed -$795K – 1912
2022
Q4 		$795K Sell
6,134
-1,136
-16% -$132K 0.1% 329
2022
Q3 		$804K Buy
7,270
+2,653
+57% +$267K 0.11% 259
2022
Q2 		$346K Sell
4,617
-1,215
-21% -$89.4K 0.05% 735
2022
Q1 		$456K Sell
5,832
-2,205
-27% -$169K 0.06% 599
2021
Q4 		$724K Buy
+8,037
New +$687K 0.09% 369
2021
Q3 		– Sell
-3,403
Closed -$265K – 1752
2021
Q2 		$265K Buy
+3,403
New +$258K 0.03% 1023
2021
Q1 		– Sell
-1,520
Closed -$259K – 1477
2020
Q4 		$259K Sell
1,520
-1,624
-52% -$241K 0.04% 824
2020
Q3 		$442K Buy
+3,144
New +$478K 0.07% 470
2019
Q4 		– Sell
-6,961
Closed -$524K – 1714
2019
Q3 		$524K Buy
+6,961
New +$822K 0.07% 522
2019
Q2 		– Sell
-2,597
Closed -$310K – 1713
2019
Q1 		$310K Buy
+2,597
New +$334K 0.03% 973
2015
Q4 		– Sell
-6,245
Closed -$201K – 1952
2015
Q3 		$201K Buy
+6,245
New +$212K 0.01% 1575

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GSA Capital Partners's SRPT Position: Q2 2026 in Review

GSA Capital Partners increased its Sarepta Therapeutics (SRPT) stake by 14% in Q2 2026, buying an estimated $239K and bringing the position to 103,618 shares worth $1.86M. The position accounts for 0.12% of the portfolio, ranked #194.

GSA Capital Partners first reported a position in SRPT in Q3 2015 and has held it in 21 quarters since. The position peaked at $1.98M in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • GSA Capital Partners held 103,618 shares of Sarepta Therapeutics worth $1.86M as of Q2 2026.
  • GSA Capital Partners bought 12,658 Sarepta Therapeutics shares in Q2 2026, an estimated $239K.
  • Sarepta Therapeutics made up 0.12% of GSA Capital Partners's portfolio in Q2 2026, its #194 holding.
  • GSA Capital Partners first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 21 quarters since.
  • GSA Capital Partners's Sarepta Therapeutics position peaked at $1.98M in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.